| 0.25 mg daily | Human | human | Not reported | Not reported | Randomized trial in people · n = 299 | Crosignani 2007 |
| 0.25 mg daily | Human | human | Not reported | Not reported | Randomized trial in people · n = 205 | Mochtar 2004 |
| 0.25 mg/day | Human | human | Not reported | Not reported | Randomized trial in people · n = 203 | Lambalk 2006 |
| 0.25 mg/day | Human | human | Not reported | Not reported | Randomized trial in people · n = 173 | Beguería 2019 |
| 0.25 mg daily | Human | human | subcutaneous | 7 days | Randomized trial in people · n = 122 | Choudhary 2021 |
| 0.25 mg/day | Human | human | Not reported | Not reported | Randomized trial in people | Giles 2021 |
| 0.0625, 0.125, 0.25, 0.5, 1.0 and 2.0 mg once daily | Human | human | subcutaneous | approximately 5 days | Randomized trial in people · n = 333 | 1998 |
| 0.0625-2.0 mg/d | Human | human | Not reported | Not reported | Randomized trial in people · n = 311 | de 2001 |
| 0.25 mg/d | Human | human | Not reported | Not reported | Randomized trial in people · n = 201 | Luo 2021 |
| 0.25 mg daily | Human | human | SC | Not reported | Randomized trial in people · n = 185 | Wilcox 2005 |
| 0.25 mg each | Human | human | Not reported | until the day of HCG administration | Randomized trial in people · n = 73 | Messinis 2005 |
| 0.125, 0.250 or 0.500 mg daily | Human | human | subcutaneous | 7 days | Randomized trial in people · n = 24 | Hohmann 2005 |
| 2 mg once daily | Human | human | subcutaneous | 7 days | Randomized trial in people · n = 16 | Oberyé 2000 |
| 0.25 mg | Human | human | subcutaneous | Single injection | Randomized trial in people · n = 15 | Oberyé 1999 |
| 0.25 mg | Human | human | subcutaneous | on average 9 days (ganirelix regimen) | Randomized trial in people | 2001 |
| 0.0625 mg | Human | human | subcutaneous | approximately 5 days | Randomized trial in people | 1998 |
| 2 mg | Human | human | subcutaneous | approximately 5 days | Randomized trial in people | 1998 |
| 0.25 mg | Human | human | subcutaneous | approximately 5 days | Randomized trial in people | 1998 |
| 0.125, 0.25, or 0.50 mg once daily | Human | human | subcutaneous | 7 days | Randomized trial in people | Oberyé 1999 |
| 0.25 mg/d | Human | human | Not reported | Not reported | Trial in people without random groups · n = 93 | Bakas 2011 |
| 0.25 mg/d | Human | human | Not reported | 3 days | Trial in people without random groups · n = 35 | Sirayapiwat 2007 |
| 0.25 mg daily | Human | human | Not reported | Not reported | Trial in people without random groups · n = 35 | Sirayapiwat 2013 |
| 0.125 mg once daily | Human | human | subcutaneous | 7 days | Trial in people without random groups · n = 15 | Oberyé 1999 |
| 0.25 mg once daily | Human | human | subcutaneous | 7 days | Trial in people without random groups · n = 15 | Oberyé 1999 |
| 0.50 mg once daily | Human | human | subcutaneous | 7 days | Trial in people without random groups · n = 15 | Oberyé 1999 |
| 0.25 mg/day | Human | human | subcutaneous | from cycle day 2 until the day of the endogenous LH surge onset in cycle 1 | Trial in people without random groups · n = 10 | Pousias 2019 |
| 0.0625 mg | Human | human | Not reported | single dose | Trial in people without random groups · n = 10 | Cotellessa 2026 |
| 0.025 mg | Human | human | Not reported | single dose | Trial in people without random groups · n = 8 | Cotellessa 2026 |
| 0.125 mg | Human | human | subcutaneous | approximately 5 days | Trial in people without random groups | 1998 |
| 1 mg | Human | human | subcutaneous | approximately 5 days | Trial in people without random groups | 1998 |
| Dose groups other than 1 mg and 2 mg (includes 0.0625 mg and 0.5 mg) | Human | human | subcutaneous | approximately 5 days | Trial in people without random groups | 1998 |
| 2 mg/day | Human | human | Not reported | Not reported | Trial in people without random groups | Simon 2005 |
| 0.25 mg/day (standard) and 2 mg/day (high) | Human | human | Not reported | Not reported | Trial in people without random groups | Simon 2005 |
| 0.25 mg/day | Human | human | Not reported | Not reported | Trial in people without random groups | Simon 2005 |
| 1 mg | Human | human | subcutaneous | 8 days | Trial in people without random groups | Nelson 1995 |
| 2 mg | Human | human | subcutaneous | 8 days | Trial in people without random groups | Nelson 1995 |
| 1 mg or 2 mg daily | Human | human | subcutaneous | 8 days | Trial in people without random groups | Nelson 1995 |
| 0.125 mg daily | Human | human | subcutaneous | 7 days | Trial in people without random groups | Hohmann 2005 |
| 0.250 mg daily | Human | human | subcutaneous | 7 days | Trial in people without random groups | Hohmann 2005 |
| 0.500 mg daily | Human | human | subcutaneous | 7 days | Trial in people without random groups | Hohmann 2005 |
